CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $5.77.

A number of equities analysts have weighed in on CTMX shares. StockNews.com cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 17th. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th.

Institutional Trading of CytomX Therapeutics

A number of hedge funds have recently made changes to their positions in CTMX. Congress Park Capital LLC grew its position in shares of CytomX Therapeutics by 393.3% during the second quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock worth $1,407,000 after buying an additional 919,420 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of CytomX Therapeutics by 206.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock worth $1,511,000 after buying an additional 833,825 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of CytomX Therapeutics during the second quarter worth approximately $467,000. Candriam S.C.A. acquired a new stake in shares of CytomX Therapeutics during the second quarter worth approximately $256,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter worth approximately $124,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

CTMX opened at $1.15 on Friday. The firm has a 50 day moving average price of $1.21 and a 200 day moving average price of $1.64. The company has a market cap of $89.61 million, a PE ratio of 5.75 and a beta of 1.04. CytomX Therapeutics has a 1 year low of $1.04 and a 1 year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $25.12 million for the quarter, compared to analyst estimates of $21.79 million. CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. During the same period last year, the company posted ($0.02) EPS. On average, sell-side analysts predict that CytomX Therapeutics will post -0.2 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.